1 study found for:    GIST | Open Studies | Japan
Show Display Options
Rank Status Study
1 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)

Indicates status has not been verified in more than two years